Selected research
Market Analysis & Forecast
Global Canine Cancer Screening Market Analysis and Forecast 2026-2032
Market perspective
The global Canine Cancer Screening market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Canine Cancer Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Canine Cancer Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Canine Cancer Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Canine Cancer Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Canine Cancer Screening include IDEXX, Mars Pedtcare, Zoetis, PetDx, Molecular Diagnostics (MDxHealth), Biomérieux SA, OncoK9, Antech Diagnostics and VolitionRx Limited, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Canine Cancer Screening, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Canine Cancer Screening, also provides the revenue of main regions and countries. Of the upcoming market potential for Canine Cancer Screening, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Canine Cancer Screening revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Canine Cancer Screening market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Canine Cancer Screening revenue, projected growth trends, production technology, application and end-user industry.
Canine Cancer Screening Segment by Company
IDEXX
Mars Pedtcare
Zoetis
PetDx
Molecular Diagnostics (MDxHealth)
Biomérieux SA
OncoK9
Antech Diagnostics
VolitionRx Limited
Oncotect
Heska Corporation
Canine Cancer Screening Segment by Type
Liquid Biopsy (Blood-Based Tests)
Tissue Biopsy
Genomic Testing
Biomarker Tests
Canine Cancer Screening Segment by Application
Veterinary Clinics
Veterinary Hospitals
Other
Canine Cancer Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Canine Cancer Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Canine Cancer Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Canine Cancer Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Canine Cancer Screening in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Canine Cancer Screening company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Canine Cancer Screening revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liquid Biopsy (Blood-Based Tests)
- Tissue Biopsy
- Genomic Testing
- Biomarker Tests
Applications
- Veterinary Clinics
- Veterinary Hospitals
- Other
Companies covered
- IDEXX
- Mars Pedtcare
- Zoetis
- PetDx
- Molecular Diagnostics (MDxHealth)
- Biomérieux SA
- OncoK9
- Antech Diagnostics
- VolitionRx Limited
- Oncotect
- Heska Corporation
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Canine Cancer Screening Market by Type
- 1.2.1 Global Canine Cancer Screening Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Liquid Biopsy (Blood-Based Tests)
- 1.2.3 Tissue Biopsy
- 1.2.4 Genomic Testing
- 1.2.5 Biomarker Tests
- 1.3 Canine Cancer Screening Market by Application
- 1.3.1 Global Canine Cancer Screening Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Veterinary Clinics
- 1.3.3 Veterinary Hospitals
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Canine Cancer Screening Market Dynamics
- 2.1 Canine Cancer Screening Industry Trends
- 2.2 Canine Cancer Screening Industry Drivers
- 2.3 Canine Cancer Screening Industry Opportunities and Challenges
- 2.4 Canine Cancer Screening Industry Restraints
3 Global Growth Perspective
- 3.1 Global Canine Cancer Screening Market Perspective (2021-2032)
- 3.2 Global Canine Cancer Screening Growth Trends by Region
- 3.2.1 Global Canine Cancer Screening Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Canine Cancer Screening Market Size by Region (2021-2026)
- 3.2.3 Global Canine Cancer Screening Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Canine Cancer Screening Revenue by Players
- 4.1.1 Global Canine Cancer Screening Revenue by Players (2021-2026)
- 4.1.2 Global Canine Cancer Screening Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Canine Cancer Screening Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Canine Cancer Screening Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Canine Cancer Screening Key Players Headquarters & Area Served
- 4.4 Global Canine Cancer Screening Players, Product Type & Application
- 4.5 Global Canine Cancer Screening Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Canine Cancer Screening Market CR5 and HHI
- 4.6.3 2025 Canine Cancer Screening Tier 1, Tier 2, and Tier 3
5 Canine Cancer Screening Market Size by Type
- 5.1 Global Canine Cancer Screening Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Canine Cancer Screening Revenue by Type (2021-2032)
- 5.3 Global Canine Cancer Screening Revenue Market Share by Type (2021-2032)
6 Canine Cancer Screening Market Size by Application
- 6.1 Global Canine Cancer Screening Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Canine Cancer Screening Revenue by Application (2021-2032)
- 6.3 Global Canine Cancer Screening Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 IDEXX
- 7.1.1 IDEXX Company Information
- 7.1.2 IDEXX Business Overview
- 7.1.3 IDEXX Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.1.4 IDEXX Canine Cancer Screening Product Portfolio
- 7.1.5 IDEXX Recent Developments
- 7.2 Mars Pedtcare
- 7.2.1 Mars Pedtcare Company Information
- 7.2.2 Mars Pedtcare Business Overview
- 7.2.3 Mars Pedtcare Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.2.4 Mars Pedtcare Canine Cancer Screening Product Portfolio
- 7.2.5 Mars Pedtcare Recent Developments
- 7.3 Zoetis
- 7.3.1 Zoetis Company Information
- 7.3.2 Zoetis Business Overview
- 7.3.3 Zoetis Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.3.4 Zoetis Canine Cancer Screening Product Portfolio
- 7.3.5 Zoetis Recent Developments
- 7.4 PetDx
- 7.4.1 PetDx Company Information
- 7.4.2 PetDx Business Overview
- 7.4.3 PetDx Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.4.4 PetDx Canine Cancer Screening Product Portfolio
- 7.4.5 PetDx Recent Developments
- 7.5 Molecular Diagnostics (MDxHealth)
- 7.5.1 Molecular Diagnostics (MDxHealth) Company Information
- 7.5.2 Molecular Diagnostics (MDxHealth) Business Overview
- 7.5.3 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.5.4 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Product Portfolio
- 7.5.5 Molecular Diagnostics (MDxHealth) Recent Developments
- 7.6 Biomérieux SA
- 7.6.1 Biomérieux SA Company Information
- 7.6.2 Biomérieux SA Business Overview
- 7.6.3 Biomérieux SA Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.6.4 Biomérieux SA Canine Cancer Screening Product Portfolio
- 7.6.5 Biomérieux SA Recent Developments
- 7.7 OncoK9
- 7.7.1 OncoK9 Company Information
- 7.7.2 OncoK9 Business Overview
- 7.7.3 OncoK9 Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.7.4 OncoK9 Canine Cancer Screening Product Portfolio
- 7.7.5 OncoK9 Recent Developments
- 7.8 Antech Diagnostics
- 7.8.1 Antech Diagnostics Company Information
- 7.8.2 Antech Diagnostics Business Overview
- 7.8.3 Antech Diagnostics Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.8.4 Antech Diagnostics Canine Cancer Screening Product Portfolio
- 7.8.5 Antech Diagnostics Recent Developments
- 7.9 VolitionRx Limited
- 7.9.1 VolitionRx Limited Company Information
- 7.9.2 VolitionRx Limited Business Overview
- 7.9.3 VolitionRx Limited Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.9.4 VolitionRx Limited Canine Cancer Screening Product Portfolio
- 7.9.5 VolitionRx Limited Recent Developments
- 7.10 Oncotect
- 7.10.1 Oncotect Company Information
- 7.10.2 Oncotect Business Overview
- 7.10.3 Oncotect Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.10.4 Oncotect Canine Cancer Screening Product Portfolio
- 7.10.5 Oncotect Recent Developments
- 7.11 Heska Corporation
- 7.11.1 Heska Corporation Company Information
- 7.11.2 Heska Corporation Business Overview
- 7.11.3 Heska Corporation Canine Cancer Screening Revenue and Gross Margin (2021-2026)
- 7.11.4 Heska Corporation Canine Cancer Screening Product Portfolio
- 7.11.5 Heska Corporation Recent Developments
8 North America
- 8.1 North America Canine Cancer Screening Revenue (2021-2032)
- 8.2 North America Canine Cancer Screening Revenue by Type (2021-2032)
- 8.2.1 North America Canine Cancer Screening Revenue by Type (2021-2026)
- 8.2.2 North America Canine Cancer Screening Revenue by Type (2027-2032)
- 8.3 North America Canine Cancer Screening Revenue Share by Type (2021-2032)
- 8.4 North America Canine Cancer Screening Revenue by Application (2021-2032)
- 8.4.1 North America Canine Cancer Screening Revenue by Application (2021-2026)
- 8.4.2 North America Canine Cancer Screening Revenue by Application (2027-2032)
- 8.5 North America Canine Cancer Screening Revenue Share by Application (2021-2032)
- 8.6 North America Canine Cancer Screening Revenue by Country
- 8.6.1 North America Canine Cancer Screening Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Canine Cancer Screening Revenue by Country (2021-2026)
- 8.6.3 North America Canine Cancer Screening Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Canine Cancer Screening Revenue (2021-2032)
- 9.2 Europe Canine Cancer Screening Revenue by Type (2021-2032)
- 9.2.1 Europe Canine Cancer Screening Revenue by Type (2021-2026)
- 9.2.2 Europe Canine Cancer Screening Revenue by Type (2027-2032)
- 9.3 Europe Canine Cancer Screening Revenue Share by Type (2021-2032)
- 9.4 Europe Canine Cancer Screening Revenue by Application (2021-2032)
- 9.4.1 Europe Canine Cancer Screening Revenue by Application (2021-2026)
- 9.4.2 Europe Canine Cancer Screening Revenue by Application (2027-2032)
- 9.5 Europe Canine Cancer Screening Revenue Share by Application (2021-2032)
- 9.6 Europe Canine Cancer Screening Revenue by Country
- 9.6.1 Europe Canine Cancer Screening Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Canine Cancer Screening Revenue by Country (2021-2026)
- 9.6.3 Europe Canine Cancer Screening Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Canine Cancer Screening Revenue (2021-2032)
- 10.2 China Canine Cancer Screening Revenue by Type (2021-2032)
- 10.2.1 China Canine Cancer Screening Revenue by Type (2021-2026)
- 10.2.2 China Canine Cancer Screening Revenue by Type (2027-2032)
- 10.3 China Canine Cancer Screening Revenue Share by Type (2021-2032)
- 10.4 China Canine Cancer Screening Revenue by Application (2021-2032)
- 10.4.1 China Canine Cancer Screening Revenue by Application (2021-2026)
- 10.4.2 China Canine Cancer Screening Revenue by Application (2027-2032)
- 10.5 China Canine Cancer Screening Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Canine Cancer Screening Revenue (2021-2032)
- 11.2 Asia Canine Cancer Screening Revenue by Type (2021-2032)
- 11.2.1 Asia Canine Cancer Screening Revenue by Type (2021-2026)
- 11.2.2 Asia Canine Cancer Screening Revenue by Type (2027-2032)
- 11.3 Asia Canine Cancer Screening Revenue Share by Type (2021-2032)
- 11.4 Asia Canine Cancer Screening Revenue by Application (2021-2032)
- 11.4.1 Asia Canine Cancer Screening Revenue by Application (2021-2026)
- 11.4.2 Asia Canine Cancer Screening Revenue by Application (2027-2032)
- 11.5 Asia Canine Cancer Screening Revenue Share by Application (2021-2032)
- 11.6 Asia Canine Cancer Screening Revenue by Country
- 11.6.1 Asia Canine Cancer Screening Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Canine Cancer Screening Revenue by Country (2021-2026)
- 11.6.3 Asia Canine Cancer Screening Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Canine Cancer Screening Revenue (2021-2032)
- 12.2 SAMEA Canine Cancer Screening Revenue by Type (2021-2032)
- 12.2.1 SAMEA Canine Cancer Screening Revenue by Type (2021-2026)
- 12.2.2 SAMEA Canine Cancer Screening Revenue by Type (2027-2032)
- 12.3 SAMEA Canine Cancer Screening Revenue Share by Type (2021-2032)
- 12.4 SAMEA Canine Cancer Screening Revenue by Application (2021-2032)
- 12.4.1 SAMEA Canine Cancer Screening Revenue by Application (2021-2026)
- 12.4.2 SAMEA Canine Cancer Screening Revenue by Application (2027-2032)
- 12.5 SAMEA Canine Cancer Screening Revenue Share by Application (2021-2032)
- 12.6 SAMEA Canine Cancer Screening Revenue by Country
- 12.6.1 SAMEA Canine Cancer Screening Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Canine Cancer Screening Revenue by Country (2021-2026)
- 12.6.3 SAMEA Canine Cancer Screening Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst